Mavrilimumab

Drug Profile

Mavrilimumab

Alternative Names: Anti-GM-CSFR monoclonal antibody - MedImmune; CAM-3001

Latest Information Update: 15 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zenyth Therapeutics
  • Developer MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 30 May 2017 MedImmune terminates a phase II extension trial for Rheumatoid arthritis due to future clinical development plans including ethical considerations in Argentina, Bulgaria, Chile, Columbia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Israel, Japan, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Ukraine and United Kingdom (SC) (NCT01712399)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2015 MedImmune completes a phase II extension trial for Rheumatoid arthritis in Argentina, Bulgaria, Chile, Columbia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Israel, Japan, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Ukraine and United Kingdom (SC) (NCT01712399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top